Biosergen

"It is exciting to advance to this next stage of dosing with BSG005," said Tine Olesen, CEO of Biosergen. "For patients with no effective options, BSG005 has the potential to be lifesaving, especially if the promising safety and efficacy results from the first cohort continue. As we progress through dose escalation, we hope to continue to observe no severe side effects, allowing us to gain deeper insights into BSG005's potential for patients in critical need."

Following positive safety and efficacy results from the first cohort, the trial's independent Data Safety Review Committee approved progression to higher dosing in this second cohort. This phase initiates patient treatment at 0.8 mg/kg per day, with potential escalation up to 1.5 mg/kg depending on patient response and safety.

The second cohort will include up to five patients and is performed in collaboration with Biosergen's partners in India, as with the first cohort. Biosergen aims to develop BSG005 as a new standard for treating invasive fungal infections in patients who are resistant to existing treatments or are ineligible for such treatment due to kidney impairment.